This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Published July 18, 2025 • Updated 3 hours ago Ned Pagliarulo Lead Editor post share post print email license The U.S. While the two treatments are constructed differently, they both use the same kind of engineeredvirus to deliver a replacement gene to the body’s muscles.
For years, the company was primarily known for licensing its C1 platform for the development of therapeutic biologics and vaccines. Our C1 and Dapibus™ production platforms remain the engines we expect to drive commercial execution. The rebranding reflects our top priority: to deliver high-value input proteins at commercial scale.”
For example, a CDMO with deep sequencing knowledge and a proprietary cell line will achieve significantly better performance than CDMOs that license third-party technologies. The first concern is microbial contamination. CDMOs must routinely test throughout CLD to ensure cell cultures are free of microbes.
Ltd (“Juyou”), a biotechnology company that develops and sells medical and cosmetic skincare products, for the commercialization and development of Pliaglis ® in mainland China (the “License Agreement”).
million and US$1.8 For additional information, please visit [link].
That’s how easy it’s for SARS-CoV-2, the virus that causes COVID-19, to enter your nose. Anderson Professor of Chemical and Biomolecular Engineering, and his colleagues, are reporting in iScience the event of an intranasal subunit vaccine that gives durable local immunity against inhaled pathogens. Breathe in, exhale.
05, 2021 (GLOBE NEWSWIRE) — ViGeneron GmbH , a gene therapy company, today announced a global collaboration and licensing agreement with Biogen Inc. USA) to develop and commercialize gene therapy products based on adeno-associated virus (AAV) vectors to treat inherited eye diseases. .
MUNICH, Germany, Jan.
Hasan Jafri , Chief Medical Officer of Aridis Pharmaceuticals, will be a speaker on a panel entitled “Direct Antivirals and Other Agents Against SARS-CoV2 Virus.” ” Panel: Direct Antivirals and Other Agents Against SARS-CoV2 Virus
Date: Wednesday, October 28, 2020
Time: 10:30AM- 11:50AM ET.
Gilead sues Russia over a compulsory license issued to a company making remdesivir ( STAT ).
WHO is closely monitoring 10 Covid variants as virus mutates around the world ( CNBC ) .
ENABLE: an engine for European antibacterial drug discovery and development ( Nature ).
iosBio , a UK-based biotechnology company, has announced an exclusive worldwide licensing agreement with ImmunityBio , a clinical-stage immunotherapy company, for rights to use iosBio’s OraPro vaccine platform technology to test the oral administration of ImmunityBio’s vaccine candidate.
The research is part of an ongoing collaboration between Columbia University and Tonix that focuses on T cell and antibody responses to SARS-CoV-2 (CoV-2), the virus that causes COVID-19. The research encompasses two projects. The study led by Dr. Ilya Trakht, Ph.D., About TNX-1800. 1 Noyce RS, et al. 2018) PLoS One. 13(1):e0188453.
MP0420 is subject to an option and license agreement with Novartis AG to develop, manufacture and commercialize Molecular Partners’ anti-COVID-19 DARPin® program. The DARPin® platform is a fast and cost-effective drug discovery engine, producing drug candidates with optimized properties for development and very high production yields.
Published July 23, 2025 Ben Fidler Senior Editor post share post print email license The executive leadership team of Dispatch Bio, as well as scientific cofounder Carl June and board chair Jeff Marrazzo. Treatments made from a patient’s own cells and engineered in a lab to attack cancer have come of age, too.
doi: 10.2210/rcsb_pdb/goodsell-gallery-048 The Virus that Cures It’s been over 25 years since the science magazine Discover first ran an extraordinary article about how a long-forgotten medical treatment, used in the former Soviet country of Georgia, could save us from the growing threat of untreatable, drug-resistant infections.
Boehringer Ingelheim and the Agency for Science, Technology and Research (A*STAR) today announced a global licensing agreement under which Boehringer Ingelheim will obtain exclusive worldwide rights to research, develop and commercialize products based on a panel of innovative, tumor-specific antibodies from A*STAR. star.edu.sg.
a San Diego-based biotechnology company with an array of technology platforms for antibody discovery and optimization, and novel NK and T cell engager generation, today announced licensing of a panel of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development.
This is Codon Digest, a weekly roundup of research papers, news articles, and industry highlights about engineered biology. Read Biological Engineering mScarlet3: a brilliant and fast-maturing red fluorescent protein. CRISPRi-mediated tunable control of gene expression level with engineered single-guide RNA in Escherichia coli.
Novavax licensed and transferred its manufacturing technologies to enable Takeda to develop and manufacture the vaccine at its facility in Hikari. Additional therapeutics: The company has assessed existing Takeda products for activity against the COVID-19 virus and co-founded the COVID R&D Alliance.
Novartis has been granted an option to in-license global rights of MP0420 and MP0423 – multi-targeted direct-acting antiviral therapeutic candidates demonstrating potential efficacy against COVID-19.
These building blocks are designed to target different sites on the virus for multiple concurrent effects.
Takeda has granted a license to HilleVax for the exclusive development and commercialization rights to its norovirus vaccine candidate, HIL-214 (formerly TAK-214), worldwide outside of Japan, in exchange for upfront consideration, as well as future cash milestones and royalties on net sales. About HilleVax.
BT-001 is a best-in-class oncolytic Vaccinia virus. platform and its patented large-capacity VV cop TK-RR- oncolytic virus, which has been engineered to encode both a Treg-depleting human recombinant anti-CTLA4 antibody generated by BioInvent’s proprietary n-CoDeR ® /F.I.R.S.T LUND, Sweden and STRASBOURG, France , Dec.
To use it, mosquitoes are bred in exactly the same way that I’ve already described, but with one major difference: Instead of infecting females with a bacterium, they are genetically engineered to express the Cas9 protein (one part of the CRISPR system ), while male mosquitoes are engineered to express guide RNAs.
To use it, mosquitoes are bred in exactly the same way that I’ve already described, but with one major difference: Instead of infecting females with a bacterium, they are genetically engineered to express the Cas9 protein (one part of the CRISPR system ), while male mosquitoes are engineered to express guide RNAs.
But for a recent paper out of Nanjing, China, researchers engineered another enzyme and showed that, when mixed with FAST-PETase, the two worked together to break down plastic twice as fast as the Texas enzyme alone. Another paper recently reported an engineered Cas protein that is “up to 11.3-fold No longer.
But for a recent paper out of Nanjing, China, researchers engineered another enzyme and showed that, when mixed with FAST-PETase, the two worked together to break down plastic twice as fast as the Texas enzyme alone. Another paper recently reported an engineered Cas protein that is “up to 11.3-fold No longer.
Pascal Soriot, Chief Executive Officer, said: “The long-acting antibody combination has the potential to offer almost immediate protection to those who are not able to be vaccinated, to both prevent infection or treat the disease in patients already infected with the virus. Financial considerations. Source link:[link].
At best, the corporations with the best models released weak versions to the public under non-commercial licenses. On the surface, they hadn't deviated much from the early 2020s: a virus infected a cell and released the genetic therapy hidden within. The pessimism of just a few years before was replaced with exuberant optimism.
The award honors McHutchison’s work in developing life-changing and curative therapies for patients with the hepatitis C virus. Additionally, Sarah Haecker Meeks, joined the Company as vice president of Business Development and Steve Nardi joined as vice president of Manufacturing and Engineering Operations.
TNX-1500 is a third generation anti-CD40-ligand mAb that has been designed by protein engineering to decrease Fc?RII Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering.
Published July 21, 2025 Ben Fidler Senior Editor Ned Pagliarulo Lead Editor post share post print email license Courtesy of Sarepta One month ago, a 51-year-old man treated in a clinical trial with an experimental gene therapy became dangerously sick.
With the depth and breadth of our current portfolio, the tremendous potential of our pipeline and scientific engine, and the power of our culture of innovation, we are poised to continue delivering meaningful value to patients by addressing some of the world’s most difficult health challenges.”. BNT162 mRNA-based Vaccine Program.
None of the products discussed thus far should be confused with “synthetic biotics” “Synthetic biotics,” also referred to as engineered living therapeutics , are bacteria that have been genetically altered to perform a specific function for diagnostic or therapeutic benefit. Thus, they could also technically be considered synthetic biotics.
Thanks to recent breakthroughs 3 in cell engineering and photosynthetic biomanufacturing, it is now possible to cost-effectively manufacture, at large scale, mucosally delivered biologics. Seven years ago, Lumen scientists discovered methods for genetic engineering of spirulina and production of exogenous proteins, such as vaccine antigens.
Now, college tuition includes a fee to license an e-textbook for a limited time. A French major wanting to become an engineer would have to start over, taking very different courses. Tomes were split into shorter versions, like calving icebergs. The first E-books date from the 1990s. ” That definition covers all bases.
Transgene and BioInvent received approval from France’s national regulatory agency to begin a Phase I/IIa trial of Vaccinia virus BT-001 in solid tumors. oncolytic virus (VVcopTK-RR-) and engineered to encode both a Treg-depleting human recombinant anti-CTLA4 antibody and the human GM-CSF cytokine.
And the article doesn’t mention how Pairwise engineered the mustard to be “less pungent.” The company also has licensing deals with Tropic Biosciences to make bananas that don't brown as fast and coffee with naturally low caffeine & high solubility (for instant coffee). Maybe for real this time? in a series A.
And the article doesn’t mention how Pairwise engineered the mustard to be “less pungent.” The company also has licensing deals with Tropic Biosciences to make bananas that don't brown as fast and coffee with naturally low caffeine & high solubility (for instant coffee). Maybe for real this time? in a series A.
Codon Digest is my weekly roundup of research, news, and industry highlights about engineered biology. These microbes were engineered to express tumor antigens that could “elicit T cells that were licensed by the commensal immune program but specific for a tumor,” including both CD4+ and CD8+ T cells, according to the study.
Scroll to the end for a beautiful chart about the Anthropocene & some details on insect engineering companies. It is used to prevent respiratory syncytial virus, or RSV, which causes about 60,000 hospitalizations in this age group each year. There are many other up-and-coming insect engineering startups. Let’s dive in.
Scroll to the end for a beautiful chart about the Anthropocene & some details on insect engineering companies. It is used to prevent respiratory syncytial virus, or RSV, which causes about 60,000 hospitalizations in this age group each year. There are many other up-and-coming insect engineering startups. Let’s dive in.
Kite, a Gilead Company (Nasdaq: GILD), today announced that it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death, can occur in patients treated with drugs directed against B cells.
And yet, with interim data announced today showing a vaccine candidate from Pfizer and BioNTech to have at least 90% efficacy, it seems certain a vaccine to protect against a virus that was unknown to science a year ago will be approved in the US and Europe, before the end of 2020.
Data from the registrational COMET-ICE trial also will form the basis for a Biologics License Application (BLA) submission to the FDA. Importantly, VIR-7832 also has been engineered to potentially enhance virus-specific T cell function, which could help treat and/or prevent COVID-19 infection.
is undergoing clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. (Nasdaq:NVAX) is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content